Welcome to our dedicated page for OPKO HEALTH SEC filings (Ticker: OPK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OPKO HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OPKO HEALTH's regulatory disclosures and financial reporting.
OPKO Health, Inc. (OPK) filed an amended quarterly report primarily to correct CEO certification exhibits; the amendment does not change previously reported results. For the quarter ended June 30, 2026, OPKO generated $163.6 million in revenue, slightly above $156.8 million a year earlier, driven by higher product sales and a large increase in revenue from transfer of intellectual property and other, offset by lower service revenue. Total costs and expenses fell sharply, leading to an operating loss of $7.0 million versus $60.0 million in the prior-year quarter, and a net loss of $8.4 million versus $148.4 million; loss per share improved to $(0.01) from $(0.19).
For the first six months of 2026, revenue was $287.8 million, down from $306.8 million, while the net loss narrowed to $63.3 million from $216.1 million as interest expense and other non-operating losses declined. Net cash used in operating activities improved to $62.8 million from $118.0 million. Cash, cash equivalents and restricted cash totaled $314.4 million at June 30, 2026, with total assets of $1.83 billion and shareholders’ equity of $1.18 billion. Total debt was $349.1 million, including $246.9 million of senior secured royalty financing and $89.8 million of 2029 Convertible Notes. OPKO continued its stock repurchase program, buying an additional 9.8 million shares for about $13.2 million in the first half of 2026.
OPKO Health, Inc. (OPK) filed an amended Quarterly Report for the three months ended March 31, 2026, primarily to replace an incorrect Section 302 certification and add the Chief Executive Officer’s certification; all other disclosures remain unchanged. OPKO reported total revenues of $124.2 million, down from $150.0 million a year earlier, as service revenue declined while product and IP-related revenue were modestly higher. The company recorded an operating loss of $51.0 million and a net loss of $54.8 million, both improved versus the prior-year quarter’s losses of $67.2 million and $67.6 million, respectively.
Cash, cash equivalents and restricted cash totaled $355.6 million at March 31, 2026, with net cash used in operating activities of $19.3 million, an improvement from $34.6 million used in the prior-year period. Total assets were $1.86 billion and total liabilities $652.2 million, including $246.6 million of senior secured royalty financing and $87.3 million of 2029 Convertible Notes. Under its stock repurchase program, OPKO bought back 3.95 million shares in the quarter for about $4.8 million, bringing total repurchases to roughly $92.0 million since inception.
OPKO Health, Inc. entered into an amendment to its July 17, 2024 Note Purchase Agreement, issuing additional senior secured notes with an aggregate initial principal amount of $125,000,000. These Notes mature on July 17, 2044 and bear interest at the 3‑month SOFR, subject to a 4.0% per annum floor, plus 7.5% per annum, consistent with the existing notes.
Interest is payable quarterly and is determined by profit share payments EirGen Pharma Limited receives from Pfizer under a profit share arrangement. The Notes are secured by EirGen’s royalty interest in mazdutide under a license with Eli Lilly for sales in China, with related Mazdutide Payments capped at $187.5 million, subject to certain liabilities and expenses. Royalty and Mazdutide Payments are applied first to interest and then, if available, to principal reduction.
OPKO Biologics Ltd. and EirGen guarantee the obligations and have granted security interests in certain of their assets. The amended agreement includes customary negative and financial covenants and standard events of default. The Additional Notes were privately placed under exemptions from Securities Act registration.
OPKO Health, Inc. reported that Sr. Vice President and CFO Adam Logal had 53,266 shares of common stock withheld on July 24, 2026 at $1.22 per share to satisfy tax withholding on vesting of restricted stock units. After this tax-withholding disposition, he directly owns 563,396 shares.
OPKO HEALTH, INC. executive VP-Administration and director Steven D. Rubin reported a tax-related share withholding. On 2026-07-24, 53,266 shares of common stock were withheld at $1.22 per share to satisfy tax obligations on vested restricted stock units, leaving 6,571,966 shares directly owned.
OPKO Health reported Q2 2026 total revenues of 163,580 (thousands), slightly above 156,807 (thousands) a year earlier. Service revenues declined, while product revenue and revenue from transfer of intellectual property and other increased.
Operating loss narrowed to 6,972 (thousands) from 59,981 (thousands), helped by lower service costs, reduced selling, general and administrative expenses and an 18,070 (thousands) gain on sale of assets. Net loss was 8,416 (thousands), or $0.01 per share, versus 148,441 (thousands), or $0.19, in Q2 2025.
For the first six months of 2026, net cash used in operating activities improved to 62,810 (thousands) from 117,974 (thousands). Cash, cash equivalents and restricted cash totaled 314,432 (thousands) at June 30, 2026. The company carries 246,854 (thousands) of senior secured royalty debt and 89,857 (thousands) of convertible notes, and has repurchased 9,835,105 shares for about $13.2 million under a $200.0 million buyback program. During Q2 2026 OPKO also received $18.4 million of earnout cash tied to the 2025 Labcorp oncology asset sale. Management highlights risks including continued losses, foreign exchange exposure, potential goodwill and IPR&D impairments, and an appealed foreign tax assessment of approximately $246 million that could be materially adverse if resolved unfavorably.
OPKO Health reported second quarter 2026 results and extensive pipeline progress across oncology, infectious disease and metabolic programs. ModeX advanced multiple multispecific antibody and in vivo CAR T candidates into or toward Phase 1 trials, while OPK-88006 for MASH and long-acting growth hormone antagonist OPK8801001 moved forward, alongside oral hormone and obesity candidates co-developed with Entera and an expanded Nicoya agreement for RAYALDEE in Greater China.
Total revenue for the quarter was $163.5 million, up from $156.8 million a year earlier, with pharmaceuticals benefiting from $46.1 million of intellectual property and other revenue, including $29.4 million tied to Nicoya. Diagnostics services revenue declined to $74.5 million from $101.1 million after the Labcorp oncology asset sale, but segment operations generated income of $4.8 million.
Consolidated operating loss improved to $7.0 million and net loss to $8.4 million, or $0.01 per share, versus a $148.4 million loss in the prior-year quarter. Cash, cash equivalents, marketable securities and restricted cash totaled $314.4 million, and the company repurchased $13.2 million of stock in the quarter. Management issued 2026 revenue guidance of $560–$585 million and Q3 2026 revenue guidance of $131–$142 million.
OPKO Health’s major shareholder Phillip Frost reports beneficial ownership of 255,429,406 shares of common stock, or about 34.1% of shares outstanding. This reflects holdings through Gamma Trust, Frost Nevada Investments Trust, a philanthropic foundation, stock options and restricted stock units.
The amendment is being filed solely because OPKO’s outstanding share count changed to 746,328,225 as of June 29, 2026. Frost and affiliated trusts report no transactions in OPKO common stock during the 60 days before this amendment.
OPKO Health director Prem A. Lachman received a new stock option grant. On June 18, 2026, he was awarded options for 30,000 shares of OPKO Health common stock at an exercise price of $1.42 per share. These options are compensation-related, not an open-market purchase, and bring his directly held option position reported in this filing to 30,000 derivative shares.
OPKO Health director Roger Medel received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036. Following this grant, he holds 30,000 options directly.